FDA modifies partial clinical hold on Tekmira Ebola study

April 10, 2015 1:13 PM

3 0

April 10 (Reuters) - Tekmira Pharmaceuticals Corp said the U.S. Food and Drug Administration would allow the company to continue testing its experimental Ebola treatment at a lower dose, altering the terms of a partial clinical hold on the study.

The company's application to study the treatment, TKM-Ebola, remains on partial clinical hold for doses above 0.24 mg/kg per day, Tekmira said on Friday.

Also read: UPDATE 1-TDC loses major contract with Novo Nordisk to Telenor

Read more

To category page

Loading...